View Older Stories View More Recent Stories
-
Bristol-Myers Squibb (BMY) to sell its new schizophrenia treatment in the UK for $22,500/yr, same price as in the U.S. - FT
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Bristol Myers Squibb presents real-world Camzyos data at ESC Congress
-
FDA grants breakthrough therapy status to Bristol Myers lung cancer drug
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Cantor Fitzgerald
-
FDA accepts Bristol Myers Squibb's Breyanzi application for fifth cancer type
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance
-
Bristol-Myers Squibb (BMY) call put ratio 1.2 calls to 1 put into quarter results
-
Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb and Bain Capital form immunology company with $300M
-
Bristol Myers Squibb gets FDA review for psoriatic arthritis drug
-
Raymond James Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea
-
Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
-
Bristol-Myers Squibb (BMY) call put ratio 2.5 calls to 1 put with a focus on August calls
-
UBS Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
FDA removing REMS from several CAR-T cell therapies positive for these 3 stocks - William Blair
-
Bristol-Myers Squibb (BMY) Declares $0.62 Quarterly Dividend; 5.3% Yield
-
Bristol-Myers Squibb (BMY) Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial
-
Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader
-
Bristol-Myers Squibb (BMY) Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial
-
Philogen subsidiary and Bristol-Myers (BMY) subsidiary announce licensing agreement for OncoACP3
-
Any near-term weakness in S&P 500 would provide a 'buy the dip' opportunity: JPM
-
Raymond James Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
JPMorgan Reiterates Neutral Rating on BioNTech (BNTX)
-
Citi on Bristol-Myers Squibb Co. (BMY): 'ASCO 2025: Early stage ADCs support breadth of oncology portfolio'
-
BioNTech soars 15% on cancer drug deal with Bristol Myers
-
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration
-
Bristol-Myers Squibb (BMY) and Biontech (BNTX) enter up to $11.1B Cancer Deal
-
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE
-
Bristol-Myers Squibb (BMY) Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
-
What can get the U.S. large-cap pharma sector to work?
-
RayJay on Veeva (VEEV): 'we haven’t heard any official designation on Bristol-Myers Squib’s plans for CRM going forward, our understanding is that CRM add-ons won’t be portable to Salesforce'
-
Bristol-Myers Squibb (BMY) to present data on oncology portfolio and pipeline at ASCO 2025
-
Bristol-Myers Squibb (BMY) Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.5 puts
-
Bristol-Myers Squibb (BMY) Appoints Cari Gallman as Chief Policy Officer
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $56 at BofA Securities
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 28c ; Offers Guidance
-
Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.2 puts on 38K contracts into quarter results
-
BMO Capital on Bristol-Myers Squibb Co. (BMY): 'ARISE Trial Miss Adds to More Difficult Story'
-
Truist on Bristol-Myers Squibb Co. (BMY): 'Cobenfy Failure in ARISE Likely to Pressure Shares'
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $68 at Jefferies
-
After-hours movers: Tesla, Oklo, Intuitive Surgical and more
